This work was supported by the National Key R&D Program of China (2022YFA1103900 to Fuming L.), the National Natural Science Foundation of China (82273223 to Fuming L
Your digestive system has fully adapted to the medication
r , Quantification of NMDA-induced (50 M) intracellular calcium rises (%F/F 0 ) following bath application of GLP-1 (1 M, n = 20 neurons) or GLP-1MK-801 (1 M, n = 38 neurons)
Bibcode:2012ArTox..86.1167C
While the extent of this interaction with Orlistat specifically is not studied, its a general consideration when taking GLP-1 agonists with other oral medications
FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions
